A
Anani Badje
Researcher at University of Bordeaux
Publications - 20
Citations - 1306
Anani Badje is an academic researcher from University of Bordeaux. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 6, co-authored 15 publications receiving 1086 citations. Previous affiliations of Anani Badje include Université Bordeaux Segalen.
Papers
More filters
Journal ArticleDOI
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Christine Danel,Raoul Moh,Delphine Gabillard,Anani Badje,Le Carrou J,Ouassa T,Eric Ouattara,Anzian A,Jean-Baptiste Ntakpe,Albert Minga,Gérard-Menan Kouamé,Bouhoussou F,Emieme A,Abo Kouame,Inwoley A,Toni Td,Ahiboh H,Kabran M,Rabe C,Sidibé B,Nzunetu G,Konan R,Gnokoro J,Gouesse P,Messou E,Dohoun L,Kamagate S,Yao A,Amon S,Kouame Ab,Koua A,Kouamé E,Ndri Y,Ba-Gomis O,Daligou M,Ackoundzé S,Hawerlander D,Ani A,Dembélé F,Koné F,Guéhi C,Kanga C,Koule S,Séri J,Oyebi M,Mbakop N,Makaila O,Babatunde C,Babatounde N,Bleoué G,Tchoutedjem M,Kouadio Ac,Sena G,Yededji Sy,Assi R,Bakayoko A,Mahassadi A,Attia A,Oussou A,Mobio M,Bamba D,Koman M,Horo A,Nina Deschamps,Chenal H,Sassan-Morokro M,Konate S,Aka K,Aoussi E,Journot,Nchot C,Sophie Karcher,Chaix Ml,Christine Rouzioux,Sow Ps,Perronne C,Girard Pm,Menan H,Bissagnene E,Kadio A,Ettiegne-Traore,Moh-Semdé C,Massumbuko Jm,Chêne G,Dosso M,Domoua Sk,N'Dri-Yoman T,Roger Salamon,Serge-Paul Eholié,Xavier Anglaret +89 more
TL;DR: In this African country, immediate ART and 6 months of IPT independently led to lower rates of severe illness than did deferred ART and no IPT, both overall and among patients with CD4+ counts of at least 500 cells per cubic millimeter.
Journal ArticleDOI
Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial
Anani Badje,Raoul Moh,Delphine Gabillard,Calixte Guéhi,Mathieu Kabran,Jean-Baptiste Ntakpe,Jérome Le Carrou,Gérard M Kouame,Eric Ouattara,Eugène Messou,Amani Anzian,Albert Minga,Joachim Gnokoro,Patrice Gouesse,Arlette Emieme,Thomas-d'Aquin Toni,Cyprien Rabe,Baba Sidibé,Gustave Nzunetu,Lambert Dohoun,Abo Yao,Synali Kamagate,Solange Amon,Amadou-Barenson Kouame,Aboli Koua,Emmanuel Kouamé,Marcelle Daligou,Denise Hawerlander,Simplice Ackoundzé,Serge Koule,Jonas Séri,Alex Ani,Fassery Dembélé,Fatoumata Koné,Mykayila Oyebi,Nathalie Mbakop,Oyewole Makaila,Carolle Babatunde,Nathaniel Babatunde,Gisèle Bleoué,Mireille Tchoutedjem,Alain-Claude Kouadio,Ghislaine Sena,Sahinou-Yediga Yededji,Sophie Karcher,Christine Rouzioux,Abo Kouame,Rodrigue Assi,Alima Bakayoko,Serge K Domoua,Nina Deschamps,Kakou Aka,Thérèse N'Dri-Yoman,Roger Salamon,Valérie Journot,Hughes Ahibo,Timothée Ouassa,Hervé Menan,André Inwoley,Christine Danel,Serge Eholié,Xavier Anglaret,Gérard-Menan Kouamé,Yao Abo,Serge-K. Domoua,Ben-Ahoussi Ndja,Blandine Adou,Constance Kanga,Eba Aoussi,Emmanuel Bissagnene,Olivier Ba-Gomis,Yves-Alain Zike,Claude Akakpo,Madeleine Sassan-Morokro,Max Mobio,Bamba Doféré,Koman Mesmin,Alain Attia,Alassane Mahassadi,Apollinaire Horo,Armel Oussou,Marie-Laure Chaix,Gilles Peytavin,Mariatou Koné,Kouamé N'Guessan,Raïmi Fassassi,Serge Niangoran,Annabel Desgrées-du-Loû,Rosemary Dray Spira,Kévin Jean,Romuald Konan,Franck Bohoussou,Cyril Yao-Yapi,Larissa N'guessan-Koffi,Bertine Siloué,Adoulaye Cissé,Adrienne Aboua,Sylvie Konan,Antoine Kouamé,Celestin N'Chot,Elvis Amani,Gwenaëlle Clouet,Bruno Debono,Geneviève Chêne,Mireille Dosso,Pierre-Marie Girard,Vincent Jarlier,Jean-Marie Masumbuko,Christian Perronne,Papa-Salif Sow,Serge-Paul Eholié +110 more
TL;DR: 6 months of IPT has a durable protective effect in reducing mortality in HIV-infected people, even in people with high CD4 cell counts and who have started ART.
Journal ArticleDOI
Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual question.
Serge Eholié,Anani Badje,Gérard M Kouame,Jean-Baptiste Ntakpe,Raoul Moh,Christine Danel,Xavier Anglaret +6 more
TL;DR: The evidence is now strong that initiating ART at high CD4 counts entails individual benefits worldwide, and that this is all the more true in low resource contexts where tuberculosis and other bacterial diseases are highly prevalent.
Journal ArticleDOI
Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)–Coinfected Patients With High HBV Replication
Gérard-Menan Kouamé,Anders Boyd,Raoul Moh,Anani Badje,Delphine Gabillard,Eric Ouattara,Jean-Baptiste Ntakpe,Arlette Emieme,Sarah Maylin,Mariama Abdou Chekaraou,Serge-Paul Eholié,Fabien Zoulim,Karine Lacombe,Xavier Anglaret,Christine Danel,Anrs VarBVA Study Groups +15 more
TL;DR: African HIV/HBV-coinfected adults with high HBV replication remain at heightened risk of mortality in the early ART era, and further studies are needed to assess interventions combined with early ART to decrease mortality in this population.
Journal ArticleDOI
Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data
Jennifer M. Ross,Anani Badje,Molebogeng X Rangaka,A. Sarah Walker,Adrienne E Shapiro,Katherine K. Thomas,Xavier Anglaret,Serge Eholié,Delphine Gabillard,Andrew Boulle,Gary Maartens,Robert J. Wilkinson,Robert J. Wilkinson,Robert J. Wilkinson,Nathan Ford,Jonathan E. Golub,Brian G. Williams,Ruanne V. Barnabas +17 more
TL;DR: In this paper, the effect of isoniazid preventive therapy given with antiretroviral therapy (ART) for the prevention of tuberculosis and death among people with HIV across population subgroups was estimated.